Objective: To evaluate repeat surfactant therapy for the treatment of respiratory failure associated with postsurfactant slump in extremely low birth weight infants (ELBW) by characterizing the population of premature infants who develop postsurfactant slump and measuring their response to a secondary course of surfactant therapy.
Study Design: A retrospective analysis of a cohort of all patients admitted over a 3-year period with birth weights <1000 g (ELBW infants). Information was collected by chart review and the patients were categorized into three distinct groups for analysis. Initial surfactant only, patients who received surfactant replacement therapy only for respiratory distress syndrome (RDS); repeat surfactant, patients who received both initial surfactant replacement for RDS and repeat surfactant therapy for postsurfactant slump (defined as respiratory failure after 6 days of age), and no surfactant, patients in whom no surfactant was ever administered. A respiratory severity score (RSS) was used to measure the severity of lung disease and response to surfactant therapy.
Results: Over 3 years, there were 165 ELBW infants who could develop postsurfactant slump and be eligible for repeat surfactant therapy. There were 39 infants who never received any surfactant therapy estimated gestational age (EGA) 27.7±1.7, birth weight 856±109 g) either at birth or after 6 days of life. There were 126 patients treated for RDS with initial surfactant replacement therapy (EGA 25.6±1.9 weeks, birth weight 713±179 g). Out of these RDS patients, 101 improved with an initial course of surfactant therapy (EGA 26±1.8, birth weight 751±143 g), but 25 (20% of the patients with RDS) developed postsurfactant slump and received a repeat course of surfactant therapy (EGA 24.7±1.2, birth weight 647±120 g). The repeat surfactant group (postsurfactant slump) was significantly more premature and had significantly lower birth weights compared to both the initial surfactant only group and the no surfactant ever group. Logistic regression analysis revealed that lack of antenatal steroids, earlier gestational age, and the receiving of 2 or more doses of surfactant to treat the initial RDS were significantly associated with receiving repeat surfactant therapy for postsurfactant slump. Of the 25 patients treated with a repeat course of surfactant therapy more than 70% of patients (n ¼ 18) had an improvement in their lung disease with a 15% reduction in their RSS. This improvement was significant at all time points evaluated (12, 24 , and 48 h).
Introduction
Extremely low birth weight infants (ELBW) with respiratory distress syndrome (RDS) are at high risk for death and bronchopulmonary dysplasia (BPD). The primary treatment for RDS is surfactant replacement therapy. [1] [2] [3] However, despite surfactant therapy after birth, many of these infants will again manifest an increased need for high levels of inspired oxygen and ventilatory support as early as the second week of life.
The condition of worsening respiratory failure owing to progressive atelectasis in premature infants previously treated with surfactant for RDS is known as postsurfactant slump and was first described in 1994 by Sobel and Carroll. 4 Patients with postsurfactant slump develop increasing oxygen requirements around day of life 9 through day of life 15 with a FiO 2 requirement X0.6. These patients had initially required more than three doses of surfactant to treat their RDS and were more likely to develop severe chronic lung disease requiring long-term ventilatory support. Premature infants who developed postsurfactant slump had a significantly greater incidence of BPD compared to those infants who did not manifest worsening of lung function in the second week of life, and whose initial RDS responded to less than four doses of surfactant. 4 There are many factors contributing to chronic lung disease in premature infants including barotrauma, volutrauma, oxygen toxicity and inadequate alveolar stability (atelectasis) or atelectatrauma. 5 To compensate for the hypoxia induced by progressive atelectasis from postsurfactant slump or surfactant dysfunction, many premature infants are treated with increasing FiO 2 . Exposure to high levels of oxygen results in the overproduction of reactive oxygen species and an increased presence of inflammatory mediators that in turn can worsen surfactant synthesis and function. Surfactant dysfunction then leads to a need for increased support from the mechanical ventilator to treat atelectasis leading to an increase in barotrauma and volutrauma with a concurrent worsening of the inflammatory cascade within the lung. 5 This process can again lead to a cycle of surfactant inactivation and dysfunction requiring increased respiratory support with high levels of oxygen and pressure that finally result in end stage respiratory failure from BPD.
Surfactant dysfunction can also be initiated in utero. Chorioamnionitis can lead to fetal pulmonary inflammation in premature infants increasing their risk of developing chronic lung disease. This mechanism is again consistent with surfactant inactivation from cytokines released in the fetal lung from increased numbers of inflammatory cells during chorioamnionitis. 6, 7 Recently, Merrill et al. 8 found that 75% of premature infants <30 weeks gestation who still required mechanical ventilation beyond the first week of life had dysfunctional surfactant. Surfactant dysfunction in these infants was associated with both infection and respiratory deterioration as measured by their respiratory severity scores (RSS). Furthermore, surfactant dysfunction in these patients was associated with a decrease in both surfactant protein B and surfactant protein C. 8 These findings support both the time course and the mechanism for postsurfactant slump.
Therapy for postsurfactant slump or secondary surfactant deficiency in premature infants is beginning to be studied. Pandit et al.
9 treated 10 premature infants with early chronic lung disease with a single repeat dose of surfactant. Nine of the infants had previously been diagnosed with RDS and had already been treated with surfactant. Despite the initial therapy, these patients after 7 days of life, still required mechanical ventilation with a FiO 2 >0.40. A secondary dose of surfactant was found to be effective in improving oxygenation in these patients. More recently, Bissinger et al., 10 in a case report, describe three premature infants (<27 weeks gestation) who developed acute respiratory decompensation after 1 week of life. All three were treated with a secondary course of surfactant administration with improvement in both their blood gases and their need for ventilator support.
Our objective was to characterize a population of premature infants who develop postsurfactant slump and to describe their response to a repeat or secondary course of surfactant therapy.
Methods
We performed a retrospective cohort analysis of all patients with birth weights <1000 g (n ¼ 198) consecutively admitted to the Children's Hospital of Iowa Neonatal Intensive Care Unit (NICU) over a 3-year period from 1 January 1999 to 30 December 2001. Patients were identified using the Neonatal Registry, a database on all high-risk infants treated at the Children's Hospital of Iowa.
We collected the following information by chart review: birth weight; gestational age; inborn or outborn; sex; intrauterine growth (appropriate vs small for gestational age (SGA)); antenatal corticosteroid therapy; presence of patent ductus arteriosus (PDA) requiring either indomethacin or surgical ligation; type of surfactant; type of ventilation; duration of respiratory support (mechanical ventilation or nasopharyngeal continuous positive airway pressure); presence and severity of intraventricular hemorrhage (IVH) as determined by the radiological report of head ultrasounds routinely obtained on days 7 and 42 of life, unless clinical indications as judged by the attending physician, dictated an earlier test; presence and severity of retinopathy of prematurity (ROP); incidence and cause of death; length of hospitalization and incidence of BPD (defined as the need for supplemental oxygen at 36 weeks' postmenstrual age in order to maintain oxygen saturation X94% as determined per the discretion of the attending physician).
Patients were divided into three groups: Group 1 -initial surfactant -patients who only received initial surfactant replacement therapy for RDS; Group 2 -repeat surfactant -patients who received both initial surfactant replacement for RDS and repeat surfactant therapy for postsurfactant slump defined as surfactant therapy given for respiratory failure after 6 days of age; and Group 3 -no surfactant -patients in whom no surfactant was administered. All of the patients who received surfactant after day of life 6 for postsurfactant slump had also received surfactant initially for RDS. There were no patients that only received surfactant after 6 days of life.
Our policy was not to electively intubate patients in the delivery room for prophylactic surfactant. Patients were intubated in the delivery room as needed for resuscitation. Surfactant was given within 2 h of delivery to patients who were diagnosed with RDS and required more than 0.30 FiO 2 . Although attending physicians change monthly in our NICU, the common strategy for RDS is to adjust the ventilator to maintain the arterial oxygen saturation between 85 and 95% and the PaCO 2 between 45 and 60 mm Hg. Following the first dose of surfactant, high frequency ventilation (HFV) was initiated at the discretion of the medical team. The positive and expiratory pressure (PEEP) and mean airway pressure (MAP) were adjusted to optimize lung volume at 9-rib expansion by chest radiograph. Additional doses of initial surfactant were given to patients who still required a FiO 2 >0.40.
Patients who developed postsurfactant slump after 6 days of life were first placed on HFV. If their oxygenation did not improve, repeat surfactant therapy was given to patients requiring a FiO 2 >0.70 for more than 6 to 8 h despite optimizing HFV. All patients who received repeat surfactant therapy were on HFV at that time and had the surfactant manually bagged in. Additional repeat doses were given if the FiO 2 increased above 0.70 more than 24 h after the first repeat dose.
Survanta was predominantly used to treat the initial RDS in our patients based on increased survival compared to Infasurf for patients with birth weight <600 g. 11 Once Infasurf became available at our institution, it was primarily used to treat the postsurfactant slump in our patients due to the laboratory evidence showing better reduction in surface tension in the face of surfactant inactivation. 12, 13 The severity of lung disease and response to the repeat course of surfactant was evaluated by calculating a RSS. The response to the repeat surfactant therapy was measured through a reduction in the RSS. The RSS was calculated by multiplying the FiO 2 times the MAP (mean airway pressure) and was determined from values recorded at hourly time points. The RSS is a modification of the oxygen index (OI ¼ ((fraction of inspired oxygen) Â (mean airway pressure) Â (100))/PaO 2 ) without the need for hourly PaO 2 values, allowing for a simple measure of the severity of lung disease in intubated patients with the same oxygen saturation goals. 8 We calculated an average RSS using hourly values from a 12-h period before the repeat dose as a baseline for the severity of the lung disease. As a measure of response to therapy, an average RSS was calculated using values recorded hourly from 1 to 12, 1 to 24, and 1 to 48 h after each repeat dose of surfactant. We also calculated average RSS for a 24 h period on day of life 0, 3, 7, 10, 14, 21, and 28 as a measure of the severity of lung disease over time and between the groups.
Results were analyzed using specific software (Sigma Stat 3.0 SPSS Inc., Chicago, IL, USA). The frequency of patients' characteristics and outcomes between the three groups were compared by analysis of variance (ANOVA) with the Student-Newman-Keuls method for multiple comparisons or by w 2 where appropriate. The results are presented as mean±s.d. Differences were considered significant if the P-value was 0.05 or less.
Stepwise logistic regression analysis was performed using Statistical Analysis Systems software (SAS version 9.1.3, SAS Institute, Cary, NC, USA) on all patients with RDS who were still intubated and alive after 6 days of age to determine whether baseline patient characteristics influenced the receiving of a repeat course of surfactant for postsurfactant slump. The variables included in the model were antenatal corticosteroids, number of initial doses of surfactant given for the treatment of RDS, gestational age, birth weight categories (p600, 601 to 700, 701 to 800, >800 g), gender, SGA, and outborn status.
The RSS after repeat doses of surfactant were analyzed by ANOVA with Dunnett's method for multiple comparisons. Changes in the RSS were analyzed by comparing baseline values (the RSS in the preceding 12 h) to the score 12, 24, and 48 h after the repeat dose. Each repeat dose of surfactant was analyzed separately. The results are presented, as mean±s.e. Differences were considered significant if the P-value was 0.05 or less. The RSS on days of life 0, 3, 7, 10, 14, 21, and 28 were compared between the three groups and within each group using ANOVA with the Student-Newman-Keuls method for multiple comparisons.
Results
There were 198 patients with a birth weight of <1000 g that were admitted over a 3-year period. Four infants were excluded from analysis because of multiple congenital anomalies and two patients were excluded because they were transferred to our institution after day of life 28. Figure 1 is a flow diagram delineating the outcomes of the remaining 192 patients. Twenty-seven infants died before day of life 6, leaving 165 surviving infants eligible to receive repeat surfactant therapy. There were a total of 126 infants who were treated for RDS with initial surfactant replacement (EGA 25.6±1.9 weeks, birth weight 713±179 g). Out of these initial surfactant therapy patients, there were 101 infants who received initial surfactant only and 25 infants (20%) who were treated with a repeat course of surfactant replacement therapy administered after 6 days of age for hypoxemic respiratory failure (EGA 24.7±1.2, birth weight 647±120 g). A total of 39 ELBW patients (24%) never had RDS and did not receive surfactant therapy at birth (EGA 27.7±1.7, birth weight 856±109 g). Furthermore, none of these Figure 1 Distribution of all patients with birth weights <1000 g admitted over a 3-year period based on surfactant therapy. patients developed postsurfactant slump or required repeat surfactant therapy. Table 1 lists important characteristics of our patient population. A significant difference was present between all groups for both gestational age and birth weight (P<0.001) with the no surfactant no RDS group being larger and more mature and the repeat surfactant group being smaller and more premature (Table 1) . We found that 20% of ELBW infants with RDS, who survive beyond 6 days of life, develop postsurfactant slump and were given a repeat course of surfactant replacement therapy. The patients receiving repeat surfactant therapy were significantly smaller and more premature than the patients who recovered from their RDS with just initial surfactant only ( Table 1 ). The patients receiving repeat surfactant were significantly less likely to have received antenatal steroids compared to the no surfactant ever no RDS group (64 vs 97%). Patients with postsurfactant slump who received repeat surfactant therapy also received more days of respiratory support compared to either patients requiring no surfactant or just initial surfactant only. There were no significant differences in patient characteristics between the repeat surfactant group and the initial surfactant only group, with respect to male sex, antenatal steroids, SGA, and inborn or outborn status (Table 1 ). There were also no significant differences in patient outcomes between the repeat and the initial only surfactant groups in the incidence of treated PDA, BPD, IVH (all grades), ROP (all stages), mortality at 28 days, and overall mortality (Table 2) .
Patients without RDS, who never received surfactant treatment, either initial or repeat, during their hospital course, were signifi- cantly larger and more mature than both surfactant therapy groups. The no surfactant group also had a significantly greater number of infants who were SGA (Table 1) . Patients who never received surfactant due to the absence of RDS, as expected, needed significantly less days of respiratory support (Table 2 ) with 14 (36%) never requiring intubation. The remaining had been intubated as part of their neonatal resuscitation in the delivery room. Patients without RDS (no surfactant group) had a significantly lower incidence of BPD, IVH, and ROP than both surfactant groups and were significantly less likely to need treatment for a PDA ( Table 2 ). There was no significant difference between the no surfactant and the surfactant groups with respect to male sex, outborn status, mortality at 28 days or overall mortality (Table 1 ). However, there was a trend towards increased mortality in the patients with RDS (10% initial only group, 12% repeat surfactant group) compared to only a 3% mortality in the patients without RDS that did not receive surfactant ( Table 2) . We performed logistic regression analysis on all patients with RDS who were still intubated and alive after 6 days of age making them eligible to receive repeat surfactant therapy (n ¼ 116). We found several statistically significant associations between the receiving of repeat surfactant therapy and perinatal variables. In the above population, exposure to antenatal steroids significantly reduced the risk of receiving repeat surfactant therapy for postsurfactant slump (OR 0.22, 95% CI (0.07, 0.67), P ¼ 0.008) controlling for gestational age and number of initial doses of surfactant. After controlling for antenatal steroid exposure and number of initial doses of surfactant, increasing gestational age reduced the risk of receiving repeat surfactant therapy (OR 0.72, 95% CI (0.54, 0.97), P ¼ 0.03). Furthermore, improvement after receiving only one dose of initial surfactant was associated with a reduced risk for repeat surfactant therapy (OR 0.35, 95% CI (0.13, 0.96), P ¼ 0.04) controlling for antenatal steroids and gestational age. Our logistical regression model also included birth weight, gender, SGA status, and outborn status as other potential confounding variables, but none of these were found to be significant (P>0.05) when controlled for gestational age, antenatal steroids, and number of initial doses of surfactant. Table 3 describes the modes of ventilation and types of surfactant used in this population. Patients with RDS predominantly received Survanta as their initial surfactant for RDS and were managed with a combination of high frequency and conventional ventilation. There were no significant differences among the types of initial surfactants used and the development of postsurfactant slump. Most of the patients (60%) who went on to develop postsurfactant slump received two or more doses of surfactant at birth, whereas the majority of the patients (67%) who never developed postsurfactant slump received only one dose of surfactant to treat their RDS. All infants that received two or more doses of surfactant for treatment of their RDS had a significantly greater risk of developing postsurfactant slump (relative risk 2.4, 95% CI (1.2, 4.9), P ¼ 0.02). There were 25 patients treated with a repeat course of surfactant therapy (Table 3) . Out of this group, 16 were given only one dose and nine received more than one repeat dose of surfactant. There was a median of three repeat doses used and the total number of repeat doses ranged from 2 to 5 per patient. Among patients receiving more than one repeat dose, the dosing interval ranged from 1 to 28 days. Survanta (beractant) was used for repeat therapy in seven patients (28%) and Infasurf (calfactant) was used in the remaining 18 patients (72%). The median time for giving repeat surfactant therapy was 12 days with a range from 7 to 45 days.
Repeat surfactant therapy improved oxygenation and reduced the severity of lung disease in ELBW patients with postsurfactant slump (Figure 2 ). There was a significant cumulative improvement over time in the RSS for all three time periods; 12, 24, and 48 h postrepeat surfactant therapy, compared to the baseline RSS from the preceding 12 h (Figure 2 ). Over 70% (18) of the patients had at least a 15% reduction in their RSS by 12 h after at least one of the repeat surfactant doses. Thirty percent (7) of the patients either did not respond to the repeat dose or had a reduction of less than 15% in their RSS. None of the patients receiving repeat surfactant therapy had received corticosteroids at the time of repeat surfactant, except for one infant who was on stress dose hydrocortisone for blood pressure support. This patient received hydrocortisone from 48 h before the repeat dose of surfactant to 48 h post the repeat dose.
The reason for giving a repeat course of surfactant therapy was determined from the staff neonatologist's daily progress note. There were six patients with hypoxemic respiratory failure from bacterial pneumonia (Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae) (mean of 2.5 doses of repeat surfactant, range 1 to 5 doses); three patients with pulmonary hemorrhage (mean of 1.7 doses of repeat surfactant, range 1 to 2 doses); 21 patients with recurrent diffuse atelectasis with increasing inspired oxygen and ventilator requirements (BPD or idiopathic postsurfactant slump) (mean of 1.1 doses of repeat surfactant, range 1 to 2 doses); and one patient with acute RDS with Gram-negative sepsis (one dose of repeat surfactant). Six patients received a course of repeat surfactant therapy for more than one reason. However, the presence of a PDA was not found to be associated with postsurfactant slump in patients receiving repeat surfactant therapy (Table 2) . Figure 3 depicts the average RSS calculated over 24 h, at day of life 0, 3, 7,10, 14, 21, and 28 for intubated patients in each of the three groups (repeat surfactant (postsurfactant slump), initial surfactant only and the no surfactant group). Patients who received repeat surfactant therapy were significantly more likely to experience an increase in their RSS after day of life 3. This worsening of lung disease, as measured by the RSS, was most striking between day of life 7 and day of life 10, and occurred before giving repeat surfactant (median age for repeat surfactant was day of life 12; range 7 to 45 days). The respiratory severity score (RSS) on day of life 0 for the no surfactant group was significantly less compared to both surfactant-receiving groups. Lung disease severity in the no surfactant group remained significantly less at all time points compared to the repeat surfactant (postsurfactant slump) group and was significantly less compared to the initial surfactant group at all time points except for day of life 21. The repeat surfactant (postsurfactant slump) group had significantly more severe lung disease than both the initial surfactant only group and the no surfactant group at all time points after day 3. ( þ ) There was a significant increase in the RSS between day 7 and 10 in the repeat surfactant (postsurfactant slump) group before receiving their repeat dose. (*, þ P< 0.05, analysis of variance (ANOVA), Student-Newman-Keuls).
The RSS on day of life 0 for patients without RDS (no surfactant group) was, as expected, significantly less compared to both RDS groups (initial surfactant only and repeat surfactant) (Figure 3) . Lung disease severity in the no surfactant group, as measured by the RSS, remained significantly less across all time points compared to the repeat surfactant group, and at all time points except for day of life 21 compared to the initial surfactant only group.
On day of life 0, there was no significant difference in the RSS between the initial surfactant only and the repeat surfactant groups ( Figure 3 ). As expected, the severity of RDS began to improve in both groups after initial surfactant replacement therapy as measured by the RSS on day 3 of life. However, on that day, a dichotomy was beginning to develop between the initial only and the repeat surfactant patients with a trend towards a worsening RSS (P ¼ 0.07) in the repeat surfactant group compared to the initial surfactant only group. By day 7 of life, the difference in the severity of lung disease was now significantly worse in the group that was going to require a repeat course of surfactant compared to the initial surfactant only group. The severity of lung disease from day 7 to day 28 of life in the repeat surfactant patients (postsurfactant slump group) remained significantly worse compared to the group that only required initial surfactant. Figure 3 shows data only from intubated patients, since it is a time course of the severity of lung disease for all three groups of patients as measured by the RSS. The repeat surfactant group had significantly more severe lung disease than both the initial surfactant only group and the no surfactant group at all time points after day 3. This is consistent with the finding that patients who received a repeat course of surfactant therapy had worse lung disease. There was a significant increase in the RSS between day 7 and 10 in the repeat surfactant group before receiving their repeat dose demonstrating that the repeat course of surfactant was given in response to a worsening in the patients' respiratory condition.
In all three groups, the severity of lung disease increased with time in patients who still remained intubated and mechanically ventilated over their first 28 days of life (Figure 3 ). In survivors, by day of life 28, only 15% of the no surfactant no RDS patients were still intubated compared to 66% of the initial surfactant only group and 84% of the repeat surfactant group (Table 2 ).
Discussion
Extremely low birth weight infants are at high risk for chronic lung disease. Many of these infants develop worsening lung function during the second week of life with an increase in the need for high levels of inspired oxygen and ventilatory support. Sobel and Carroll 4 used the phrase postsurfactant slump to describe this condition of worsening respiratory failure with progressive atelectasis in an infant who has been previously treated with surfactant for RDS.
Postsurfactant slump usually begins in the second week of life and infants who experience this condition are more likely to develop chronic lung disease and require prolonged ventilator and oxygen support. 4 The mechanisms responsible for postsurfactant slump may include surfactant deficiency, inactivation or dysfunction. Merrill et al., 8 found decreased levels of surfactant protein B in tracheal aspirates obtained from premature infants, <30 weeks gestation, who required mechanical ventilation beyond the first week of life and experienced a respiratory deterioration as measured by a worsening of their RSS. These samples were also found to have surfactant dysfunction as measured by a pulsating bubble surfactometer. 8 Beresford and Shaw 14 also found lower levels of surfactant protein B in samples from bronchoalveolar lavages obtain from premature infants who died in the first 2 weeks of life compared to survivors.
There are many factors that contribute to the development of chronic lung disease including barotrauma, volutrauma, oxygen toxicity, and inadequate alveolar stability or atelectasis. These factors are associated with inactivation of surfactant activity or surfactant dysfunction through the activation of an inflammatory cascade. 5, 15 Furthermore, alterations in the amount of surfactant or changes in the composition of surfactant have been found in nearly every form of lung disease including chronic, acute, infectious, and inflammatory lung diseases. 16 Impairment in surfactant production and composition can result from inhibition, degradation, or decreased production. 16, 17 Epithelial cell injury by inflammatory mediators can result in increased permeability of the microvasculature leading to leakage of protein and fluid which can also inactivate surfactant. 13, 16, 18 Out of the 25 patients in our study that required a repeat course of surfactant therapy seven (28%) had an acute infectious process, three (12%) had pulmonary hemorrhage and 21 had worsening BPD (84%) that led to their surfactant dysfunction. Six (24%) of these patients had more than one cause for their respiratory deterioration. We did not evaluate whether prenatal risk factors for BPD, such as chorioamnionitis were associated with the need for a repeat course of surfactant therapy in our patient population.
Surfactant replacement has been shown to improve gas exchange in infants with pneumonia, acute RDS and a number of other respiratory diseases in which there is surfactant dysfunction or deficiency. 18, 19 Bissinger et al. 10 described three patients with secondary surfactant deficiency or postsurfactant slump that responded to repeat courses of surfactant. At our institution, we found that 20% of ELBW infants diagnosis with RDS at birth received repeat surfactant replacement therapy in the second to sixth week of life to treat postsurfactant slump or respiratory failure associated with presumed secondary surfactant deficiency.
We identified three clinically distinct subsets of ELBW infants based on their receiving surfactant therapy. The first group of infants (no surfactant group) never had evidence of RDS and therefore never received surfactant therapy. These infants were significantly more mature with a greater gestational age, larger birth weights, and were more likely to be SGA. They were able to be successfully extubated sooner and had a lower incidence of BPD, compared to both surfactant-receiving groups (initial surfactant only and repeat surfactant), again reflecting their greater pulmonary maturity. At all stages of their hospital course, the no surfactant no RDS group had less severe lung disease compared to the RDS patients who received initial surfactant only and improved or slumped and went on to receive repeat surfactant therapy.
Both of the remaining two groups of infants received initial surfactant replacement therapy for RDS. The subset of RDS infants who received repeat surfactant therapy, were born at a significantly earlier gestational age, and were smaller at birth compared to the initial surfactant only group. Compared to the no surfactant group, these repeat surfactant infants were also less likely to have received antenatal steroids. Furthermore, logistic regression analysis of all infants treated with surfactant for RDS who were still intubated after 6 days of age found that infants who received repeat surfactant therapy for postsurfactant slump were less likely to have received antenatal steroids, more likely to have received two or more doses of surfactant for their initial RDS, and were born at an earlier gestation. Repeat surfactant therapy was administered in this group for disease processes known to inactivate endogenous surfactant including pneumonia, sepsis, pulmonary hemorrhage, and diffuse atelectasis.
At birth, there was no difference in the degree of lung injury, as measured by the RSS on day of life 0, between the initial surfactant only group and the repeat surfactant therapy group. However, more of the repeat surfactant (postsurfactant slump) patients received two or more doses of surfactant to treat their initial RDS compared to the initial surfactant only group. The receipt of multiple doses of surfactant was a harbinger for the development of postsurfactant slump and was consistent with the findings of Sobel and Carroll 4 that the need for four doses of Survanta was an early marker for postsurfactant slump.
Infants who would go on to receive repeat surfactant therapy had developed more severe lung disease by day of life 7 as measured by a significantly greater RSS. The most common time during which the postsurfactant slump presented was between days 7 and 10 of life during which a dramatic rise in the RSS occurred. The median time for receiving repeat surfactant therapy was on day 12 of life, which was after their lung function had already worsened so the repeat dose did not make them worse. By day of life 28, 15% of the no surfactant patients were still intubated compared to 66% of the initial surfactant only group and 84% of the repeat surfactant group. The prolonged need for intubation and mechanical ventilation in the repeat group is consistent with the finding that patients who received repeat surfactant therapy had a more severe degree of lung disease. Repeat therapy appears to be relatively safe in that there were no significant differences in patient outcomes between the repeat and the initial only surfactant groups in the incidence of PDA (treated), BPD, IVH (all grades), ROP (all stages), mortality at 28 days, and overall mortality ( Table 2) .
There are clear limitations to our study. It is a retrospective cohort analysis of all ELBW patients admitted over 3 years to our NICU and not a prospective randomized control trial. Thus, there can be potential bias introduced in how the patients were selected to receive repeat surfactant therapy, as well as the possibility of a coincidental resolution of the slump occurring with repeat surfactant therapy. Furthermore, since the medical team was not blinded regarding which patient received the repeat surfactant therapy, bias could potentially affect the downstream management of these patients. As all of our patients who received repeat surfactant were also on HFV, it is difficult to cleanly extrapolate our findings to patients on conventional ventilation at the time of repeat therapy. Nevertheless, we feel that our findings regarding the epidemiology of postsurfactant slump is meaningful and that the use of repeat surfactant therapy for this phenomenon may hold promise.
Overall, we found that 20% of infants less than 1000 g with RDS treated with initial surfactant replacement therapy will go on to develop a postsurfactant slump after day of life 6. Over 70% of these patients had an improvement in their lung disease with a significant reduction in their RSS after a repeat course of surfactant. This improvement in respiratory status and oxygenation after repeat surfactant therapy was consistent with previous reports by both Pandit et al. 9 and Bissinger et al. 10 . Pandit found that the effect lasted for 24 h and in the majority of our patients a significant reduction in their RSS persisted for at least 48 h. We felt that a drop in the RSS by at least 15% or more in our patients was clinically meaningful in that it demonstrated a need for less toxic levels of oxygen.
In conclusion, we found an apparent benefit of repeat surfactant therapy for the treatment of postsurfactant slump in premature infants without any increase in mortality or morbidity compared to patients that did not develop postsurfactant slump. These initial findings would support performing randomized control trials of repeat surfactant therapy for postsurfactant slump.
Abbreviations RSS, respiratory severity score; RDS, respiratory distress syndrome, BPD, bronchopulmonary dysplasia; ELBW, extremely low birth weight; ROP, retinopathy of prematurity; IVH, intraventricular hemorrhage
